191805-29-5

Usage

Uses

Used in Pharmaceutical Development:
Tert-butyl 1-oxo-8-azaspiro[4.5]decane-8-carboxylate is used as a potential drug candidate in the pharmaceutical industry due to its unique structural features and the possibility of exhibiting pharmacological properties. Its azaspiro framework and functional groups may contribute to its interaction with biological targets, making it a valuable compound for the development of new therapeutic agents.
Used in Synthesis of Biologically Active Molecules:
In the field of organic chemistry, tert-butyl 1-oxo-8-azaspiro[4.5]decane-8-carboxylate serves as a building block for the synthesis of other biologically active molecules. Its structural components can be utilized in the creation of novel compounds with potential applications in various therapeutic areas, thus expanding the scope of available treatments.
Used in Medicinal Chemistry Research:
Tert-butyl 1-oxo-8-azaspiro[4.5]decane-8-carboxylate is employed as a subject of study in medicinal chemistry research to better understand its properties, interactions with biological systems, and potential applications. This research can lead to the discovery of new mechanisms of action, optimization of its pharmacological profile, and the development of more effective drugs based on its structure.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 34619-03-9 tert-butyldicarbonate 
• 849203-09-4 (RS)-8-(1,1-dimethylethyl) 2-methyl 1-oxo-8-azaspiro[4.5]decane-2,8-dicarboxylate 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 
• 191805-27-3 ethyl 4-(4-oxo-4-phenylbutyl)-1-(tert-butyloxycarbonyl)piperidine-4-carboxylate 

Relevant academic research and scientific papers

Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors

SHP2 is a nonreceptor protein tyrosine phosphatase within the mitogen-activated protein kinase (MAPK) pathway controlling cell growth, differentiation, and oncogenic transformation. SHP2 also participates in the programed cell death pathway (PD-1/PD-L1) governing immune surveillance. Small-molecule inhibition of SHP2 has been widely investigated, including in our previous reports describing SHP099 (2), which binds to a tunnel-like allosteric binding site. To broaden our approach to allosteric inhibition of SHP2, we conducted additional hit finding, evaluation, and structure-based scaffold morphing. These studies, reported here in the first of two papers, led to the identification of multiple 5,6-fused bicyclic scaffolds that bind to the same allosteric tunnel as 2. We demonstrate the structural diversity permitted by the tunnel pharmacophore and culminated in the identification of pyrazolopyrimidinones (e.g., SHP389, 1) that modulate MAPK signaling in vivo. These studies also served as the basis for further scaffold morphing and optimization, detailed in the following manuscript.

ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES

The present invention is directed towards new chemical entities which primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity particularly involved in the development and maintenance of persistent or chronic pain, and / or neurological disorders. These novel compounds are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which these ion channels are involved. The invention is also directed towards pharmaceutical formulations comprising these compounds and the uses of these compounds.

Preparation method of tertiary butyl 1-hydroxyl-8-azaspirane[4,5]decane-8-carboxylic ester

The invention relates to a preparation method of tertiary butyl 1-hydroxyl-8-azaspirane[4,5]decane-8-carboxylic ester and mainly solves the technical problems that a method suitable for industrial synthesis does not exist at present. The preparation method comprises three steps: firstly, generating a compound 2 by a compound 1 under the action of hydrochloric acid; secondly, obtaining a compound 3 by enabling the compound 2 to react with di-tert-butyl dicarbonate in a mixed solution of dioxane and water under the existence of sodium carbonate; finally, obtaining a product 4 by treating the compound 3 through sodium borohydride, wherein a reaction formula is as shown in the description. The tertiary butyl 1-hydroxyl-8-azaspirane[4,5]decane-8-carboxylic ester obtained through the preparation method disclosed by the invention is a useful intermediate or a product compounded by many medicines.

SUBSTITUTED CYCLOHEXYL DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS

The present invention relates to the compounds of formula (I): wherein A,B, n, X, Y, Z, R1, R2, R3, R4, R5, R6, R7 and R8 are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-3 (NK-3) receptors. These compounds can thus be used in methods of treatment to suppress and treat such disorders.

Cyclopentyl modulators of chemokine receptor activity

Cyclopentyl compounds of Formula (I) are modulators of chemokine receptor activity: wherein D, G, R2, R3 and R8 in Formula (I) are defined herein. The compounds, and pharmaceutically acceptable salts and individual diastereomers thereof, are useful in the treatment and prevention of HIV infection, in delaying the onset of AIDS, and in the treatment of AIDS. The compounds are also useful for treating other diseases and conditions mediated by chemokine receptors.

4-Heterocyclylpiperidines as selective high-affinity ligands at the human dopamine D4 receptor

5-(4-Chlorophenyl)-3-(1-(4-chlorobenzyl)piperidin-4-yl)pyrazole (3) was identified from screening of the Merck sample collection as a human dopamine D4 (hD4) receptor ligand with moderate affinity (61 nM) and 4-fold selectivity over human D2 (hD2) recepto